Researchers identify new molecular targets into nonalcoholic steatohepatitis
New data shows COVID-19 vaccine does not raise stroke risk
25 August 2022New guidance to address new nonstatin therapies
25 August 2022Researchers identify new molecular targets into nonalcoholic steatohepatitis
Nonalcoholic steatohepatitis (NASH), characterized by liver steatosis, inflammation and injury, has emerged as one of major causes for end-stage liver disease like hepatocellular carcinoma. However, what drives its progression?
